Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pancreatic Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pancreatic Cancer
    TopAbstracts in Pancreatic Cancer 08/27/2008 - (DGNews)
    FDA Investigating Possible Link Between Ezetimibe/Simvastatin and Increased Cancer Risk - (DGNews)
    FDA Clears the Pathwork Tissue of Origin Test - (DGNews)
    TopAbstracts in Pancreatic Cancer 07/30/2008 - (DGNews)
    Chemotherapy and Postsurgical Radiation Prolong Life for Pancreatic Cancer Patients - (DGNews)

    News archive

     Recent webcasts/CME - Pancreatic Cancer

    Webcasts/CME archive

     Recent cases - Pancreatic Cancer
      Pancreatic Tuberculosis with Splenic Tuberculosis Mimicking Advanced Pancreatic Cancer with Splenic Metastasizes: A Case Report
      A Role for Surgery in Primary Pancreatic B-Cell Lymphoma: A Case Report
      Castleman's Disease in the Head of the Pancreas: Report of a Rare Clinical Entity and Current Perspective on Diagnosis, Treatment, and Outcome
      EUS-Guided Transduodenal Biliary Drainage in Unresectable Pancreatic Cancer with Obstructive Jaundice
      Combined Endocrine and Exocrine Tumours of the Pancreas

      Cases archive
        




      my personal edition > pancreatic cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Bevacizumab Provides Promising Add-on to Chemoradiation in Pancreatic Cancer: Presented at ASCO-GI

      By Roberta Friedman, PhD

      SAN FRANCISCO, CA -- January 26, 2004 -- Phase I data show possibilities for combining bevacizumab with radiation and capecitabine in inoperable, advanced pancreatic cancer.

      Results on 24 patients treated with bevacizumab for pancreatic cancer were presented here January 23rd at the First Annual Symposium on Gastrointestinal Cancers, jointly sponsored by the American Society of Clinical Oncology and other societies.

      Study investigator Christopher Crane, MD, of the MD Anderson Cancer Center, Houston, Texas, said that two of the patients had no cancer progression at 1-year follow up. One patient had a "dramatic" response, with radiographic complete resolution of tumor, he added. Perfusion imaging showed increased blood flow to the tumor. An intent of the antibody treatment is to correct the relative ischemia of pancreatic tumors.

      One duodenal hemorrhage due to tumor regression was healed through supportive care. One patients had a genitourinary hemorrhage during the trial. Also, an instance of grade 3 joint pain was recorded. No cases of grade 3 anemia were observed during the study. An instance of grade 3 gastrointestinal toxicity was ascribed to the chemotherapy agent.

      No proteinuria or thrombosis appeared, but five patients developed hand and foot syndrome, Dr. Crane said.

      The dose of capecitabine (650, or 900 mg/m2 orally twice daily in the first, and second and third cohorts respectively) had to be reduced by a quarter for nine of the 24 patients. All participants received a full dose of planned radiation (50.4 Gy). All doses of the antibody were given, except for one missed dose during the genitourinary hemorrhage.

      Bevacizumab was given at 5 mg/kg intravenously, two weeks before the start of radiation, and then every 2 weeks thereafter.

      Some of the authors of this study have received research funding from Genentech.


      [Study title: Preliminary results of a phase I study of rhuMab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP). Abstract OP85]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send